|
|
 |
 |
|
 |
|
| THE FINANCIER |
Research doctors from the Fred Hutchinson Cancer Research Center started at least 10 major
companies, many with help from The Hutch and New York financiers David and Isaac Blech.
|
| Company |
Stock |
Value |
52-week
high |
Founded |
Blech $
connection |
Hutch $
connection |
Genetic
Systems |
GSC |
$294 million(a) |
1980 |
yes |
Licenses,
royalties |
| Immunex |
IMNX |
$13.2
billion |
$44.9
billion |
1981 |
|
Experiments |
| NeoRX |
NERX |
$147
million |
$1.8
billion |
1984 |
yes |
Clinical trials |
Targeted
Genetics |
TGEN |
$174
million |
$1.0
billion |
1989 |
|
Licensing,
contracts |
| ICOS |
ICOS |
$2.3
billion |
$3.1
billion |
1989 |
yes |
|
| CellPro |
CPRO |
$284 million(b) |
1989 |
|
Stock,
licenses,
royalties |
Cell
Therapeutics |
CTIC |
$485
million |
$2.2
billion |
1991 |
yes |
Stock,
licenses,
royalties |
PathoGenesis
(Chiron) |
CHIR |
$700 million(c) |
1992 |
yes |
|
| Corixa |
CRXA |
$512
million |
$2.4
billion |
1994 |
|
|
| Rosetta Inpharmatics |
RSTA |
$278
million |
$1.2
billion |
1996 |
|
Stock,
licenses,
royalties
|
a) Sale price to Bristol-Myers in 1986. Bristol-Myers resold the company in 1991 for $20 million.
(b) 1997 value. Went bankrupt in 1998, after losing patent-infringement lawsuit.
(c) Sale price to Chiron in August 2000. Chiron has market cap of $8.3 billion. |
| Sources: Seattle Times research, SEC reports, Nasdaq closing values 3/13/01. The Hutchinson Center will not reveal stock holdings
or license and royalty deals, so this chart is incomplete. |
|
|
|
